neutralization of activity. 14, 15 Thus, the development of ADAbs can have negative clinical consequences by affecting either the pharmacokinetics or the pharmacodynamics of biologics, but few data suggest that ADAbs are always associated with diminished drug concentrations or loss of response. 16 While assay protocols for measuring drug concentrations are standardized, ADAb concentration and positivity may be influenced by the assay protocols, reagents, thresholds for drug interference, and timing of sampling relative to dosing. In addition, the kinetics of ADAbs are highly variable between individuals and ADAb positivity may be transient. [16] [17] [18] The interplay between these factors makes interpretation of the existing literature in this area difficult. [16] [17] [18] The incidence of immunogenicity based solely on a single positive ADAb value during the course of treatment may not be representative of whether the patient can successfully continue therapy.
Here, we evaluated the relationship between immunogenicity and drug concentrations, using data from the PRECiSE 3 trial, a 7-year open-label extension study of CZP treatment in patients with Crohn's disease. 19, 20 CZP is a subcutaneously administered humanized PEGylated, Fab 0 fragment (Fc-free antibody fragment), with specificity for TNFa. The long duration of the PRECiSE 3 trial provided the opportunity to examine the relative effects of transient or persistent expression of CZP-ADAbs on plasma concentrations of CZP, disease activity, and inflammatory biomarkers.
METHODS

Study Design
The PRECiSE 3 study design has been described previously. 20 Briefly, patients with moderate-to-severe Crohn's disease who completed PRECiSE 1 21 or PRECiSE 2 22 were eligible to enroll in PRECiSE 3 , an open-label extension study (NCT00160524). Patients in this analysis from PRECiSE 3 received CZP 400 mg every 4 weeks up to a total of 7.5 years (see Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B480).
The PRECiSE studies were conducted in compliance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. In addition, all local regulatory requirements were followed. The protocol was approved by the Institutional Review Board or Ethics Committee at each center. All patients signed an informed consent form.
Assessments and Analyses
Baseline assessments were measured at screening for the qualifying studies (PRECiSE 1 21 or PRECiSE 2 22 ). In those studies, CZP or placebo induction therapy was administered at weeks 0, 2, and 4, followed by maintenance doses of CZP or placebo every 4 weeks, with the last dose at week 24. This dosing schedule was maintained in the open-label extension PRECiSE 3. For PRECiSE 3, the safety population included all eligible patients who enrolled and received at least 1 injection of study treatment in the qualifying studies. The safety population was used for all pharmacokinetics summaries and immunological variables.
Plasma concentrations of CZP and antibodies to CZP were measured at screening for the qualifying study and during PRECiSE 3 at week 0, every 4 weeks from week 2 to week 106, and at weeks 130, 158, 182, 210, 234, 258, 318, and 364, and were determined by a specific enzyme-linked immunosorbent assay reported elsewhere 13 and briefly summarized below. Blood samples were taken before CZP administration to approximate trough concentrations. The assay for CZP had a lower limit of quantification of 0.41 mg/mL. Plasma CZP concentrations were measured in the overall population (n ¼ 594, intent-to-treat); CZP-ADAbs were assessed in the safety population with complete data (n ¼ 593).
The enzyme-linked immunosorbent assay for ADAb used biotinylated CZP, and a double antigen sandwich (bridge) format to allow detection of all classes of human antibodies with affinity for CZP. For quantification, a standard curve (range, 0.03-2.00 mg/mL) generated with an affinity-purified rabbit, anti-CZP antibody was used. CZP-ADAbs were expressed in units per milliliter, with 1 unit being equivalent to 1 mg/mL of the standard. The lower limit of quantification of ADAb, allowing for the sample dilution, was 0.06 U/mL. Patients were considered to be CZP--ADAb positive if they had at least 1 test result because baseline indicating the presence of antibodies to CZP with concentration .2.4 U/mL. 13 The presence of CZP may have interfered with the antibody assay because the drug can form complexes with the ADAb. Therefore, the definition of ADAb positive included a reduction in the plasma levels of CZP, in addition to the concentration of ADAb.
A review of the longitudinal data for ADAbs in individual patients over time was performed independently by 2 authors (G.K. and G.P.). On completion of individual assessments, the reviewers adjudicated the data together and classified patients into one of the following prospectively defined categories: transient CZP-ADAb positive (.2.4 U/mL with transient or no effect on CZP plasma concentration [.5 mg/mL], Fig. 1B ). Persistent CZP-ADAb positivity was additionally defined as evidence of abnormally low (#5 mg/mL) or declining drug concentrations on 2 or more consecutive occasions in patients where dosing compliance was documented. This low threshold for CZP concentration was initially selected subjectively to identify patients who did not have plasma concentrations within the normal range. The threshold value has been validated by calculation of the percentage of patients with CZP trough concentrations on either side of the threshold for patients who were CZP-ADAb negative (average, 86.6%; range, 81.5%-93.3%; median, 85.4%).
In reviewing the patient-level data, the investigators noted that only those with persistently positive CZP-ADAbs had consistently low drug plasma concentrations. Thus, the 3 CZP-ADAb "patterns" (transient, intermittent, recovery) were combined into a single category, called as "transient." The summary data are therefore presented as transient CZP-ADAb-positive group (with no impact, or only a temporary impact on CZP plasma concentration) and "persistent" CZP-ADAb-positive group.
In addition to the definition above, discontinuation from the study within 6 weeks of a CZP-ADAb-positive result triggered the classification of persistent ADAb category. This trigger was maintained even if (1) there was a relatively small decrease in the CZP plasma concentration; (2) CZP-ADAb .2.4 U/mL did not persist; or (3) CZP plasma concentration increased but not above a threshold for "normal" CZP plasma trough concentration of 5 mg/mL.
Harvey-Bradshaw Index (HBI) scores and CRP serum concentrations were assessed at screening of the qualifying study (PRECiSE 1 or 2) and during PRECiSE 3 at week 0, week 2, every 4 weeks from week 2 to week 106, every 8 weeks from week 106 to week 154, every 8 weeks from week 158 to week 258, then every 12 weeks until week 354, and at week 364. FCP concentrations were measured at screening for the qualifying study and at PRECiSE 3 at weeks 0, 26, 54, 82, 106, 130, 158, 182, 210, 234, and 258. HBI, CRP, and FCP were assessed in the intent-to-treat population (N ¼ 594).
All statistical analyses were based on observed cases. The Wilcoxon rank-sum test was used for statistical comparisons between persistent CZP-ADAb-positive and -negative patients. No adjustment was made for multiple testing. Kaplan-Meier plots with log-rank analyses were used to assess the time to discontinuation of CZP treatment. A 2-sided significance level of a ¼ 0.05 was used for all statistical tests.
All authors had access to the study data, and reviewed and approved this manuscript for publication.
RESULTS
Patients (Disposition/Demographics)
The safety population enrolled in PRECiSE 3 consisted of 595 patients with moderate-to-severe Crohn's disease. Of 594 patients in the intent-to-treat population, 444 patients (74.7%) were CZP-ADAb negative (e.g., antibodies to CZP were not observed at any time point) and 134 (22.6%) were CZP-ADAb positive during PRECiSE 3 or the qualifying studies (CZP-ADAb observed at least once during the study, Fig. 2 ). Sixteen (2.7%) patients were identified as CZP-ADAb-positive patients identified only during the safety follow-up visit and were not included in these analyses. Forty of the 134 certolizumab-positive patients (30%) were categorized as having transient ADAb. The remaining 94 patients (70%) in the CZP-ADAb-positive group were categorized as having persistent CZP-ADAbs (Fig. 2) . Overall, the 3 analysis groups (transient ADAb, persistent ADAb, and negative ADAb) had similar demographic and disease characteristics at baseline (Table 1) .
Of patients who were administered concomitant immunomodulators at baseline, 40% were ADAb negative whereas 33% developed transient ADAb to CZP. Only 19% of these patients developed persistent ADAb. In addition, rate of persistent ADAb positivity was higher in patients without immunomodulatory treatment ($90 d, 73/94, 78%) than for those who had longterm concurrent immunomodulator treatment (18/94, 19%) . Of the patients with long-term concurrent immunomodulatory treatment (n ¼ 206), 9% (n ¼ 18) developed persistent ADAb positivity, 6% (n ¼ 13) had transient ADAb and 85% (n ¼ 175) were ADAb negative.
CZP Plasma Concentrations by Antibodies to CZP Status
Patients with transient CZP-ADAbs had little or no change in CZP plasma concentrations (Fig. 1A , see Fig. 2A and 2B, Supplemental Digital Content 2 and 3, http://links.lww.com/IBD/B481 and http://links.lww.com/IBD/B482). By contrast, those with persistent CZP-ADAb expression had sustained reductions in plasma CZP concentrations (Fig. 1B) . At all measurements during the PRECiSE 3 study, the geometric means of CZP trough plasma concentrations were significantly lower in the persistently positive group than those who were either transiently positive or negative for CZP-ADAbs for all assessments (P # 0.0001, Fig. 3A) . No significant differences in CZP concentrations were found between patients with transient CZP-ADAb and the CZP-ADAb-negative group at any time point.
Relationship Between Antibody Status and HBI Scores
Over time, median HBI values were numerically higher in patients in the persistent CZP-ADAb-positive group than the transient CZP-ADAb-positive group and the CZPADAb-negative group up to week 158, but these differences were not statistically significant (Fig. 3B) .
Relationship Between Antibody Status, CZP, and Biomarkers of Inflammation (CRP and FCP)
Median serum CRP concentrations were significantly higher in the persistently positive CZP-ADAb group relative to the transiently positive group and the CZP-ADAb-negative group up to week 106 (P , 0.05 for each time point, Fig. 3C ). Median CRP concentrations were very similar between the transient CZPADAb group and the CZP-ADAb-negative group at all measurements. Median FCP concentrations were substantially higher in the persistently CZP-ADAb-positive group than the other 2 groups up to week 158, reaching statistical significance at the beginning of the study and at week 26 (P ¼ 0.0265 and 0.0004, respectively, Fig. 3D ). The differences in FCP concentrations between the transiently positive group and the CZP-ADAb-negative group were not statistically significant.
Study Discontinuation and Safety
Eleven percent of patients with persistently positive CZP-ADAbs completed the 7-year study. Corresponding rates for those with transient CZP-ADAbs and negative for CZP-ADAbs were 20% and 21%, respectively (Table 2 ). In addition, the The most common reason for discontinuation in all groups was adverse events (persistent CZP-ADAb 46%, transient CZP-ADAb 38%, and CZP-ADAb negative 34%). Lack of improvement in Crohn's disease or disease deterioration was reported for discontinuation in 21%, 15%, and 16% of patients, respectively. Patients could have discontinued for .1 reason.
The safety profiles were similar between the persistent CZP-ADAb-positive group and the CZP-ADAb-negative group; overall adverse events occurred in 86.2% and 87.0%, respectively, and serious adverse events were reported in 38.3% and 39.3%, respectively ( Table 2 ). The rates of events were lower for the transient CZP-ADAb-positive group (32.5% for all adverse events and 5.0% for serious adverse events), but the small population size (n ¼ 40) makes interpretation difficult. The most common adverse events in the persistent positive group and the negative groups were abdominal pain (13.8% and 15.6%, respectively), arthralgia (13.8% and 11.1%, respectively), and upper respiratory tract infection (12.8% and 8.9%, respectively). 
DISCUSSION
Summary and Interpretation of Findings
This study is the largest and longest duration (up to 7.5 yr) prospective evaluation of the effects of ADAbs on a biological drug for Crohn's disease. CZP-ADAbs are uncommon and occurred in 134/594 (22.6%) of patients in the PRECiSE 3 study. Of those who were positive for ADAb, 30% (n ¼ 40) had transient expression that was not associated with lower drug concentrations or elevated biomarkers of inflammation; however, single measurements of ADAb in this group may not provide enough information for treatment decisions. Decreases in free CZP plasma concentrations because of expression of ADAbs seemed to be limited to the patients with persistent expression (n ¼ 94).
Ungar et al 16 found that up to 46% of patients with inflammatory bowel disease being treated with infliximab developed persistent anti-infliximab antibodies that reduced the circulating concentration of the drug and impaired response. In addition, 26% of patients developed transient antibodies, defined as those occurring on nonconsecutive measurements. 16 Those patients who developed transient antibodies remained responsive to infliximab and did not require a change in treatment. The results are generally consistent with data from this study.
Measuring ADAbs can be challenging and measurements may vary from one testing method to another. The most common method of ADAb measurement is the ELISA (used in this study), which is susceptible to nonspecific binding and false-positive findings. Several commercial assays for various anti-TNF antibodies are available. A new assay for measuring CZP and CZP-ADAb has recently been introduced which may address some of these concerns (Miraca Life Sciences, Inc., Irving, TX). The time between administration of the drug and acquisition of the blood sample influences drug concentrations, which in turn affects the sensitivity of the assay. However, the protocol for PRECiSE 3 required taking blood samples just before CZP administration so that all samples approximately represent "trough" concentrations.
Clinical Implications
Reduced concentrations of anti-TNFa agents subsequent to the development of ADAbs have been implicated in loss or lack of treatment responses. 10, 23, 24 In this analysis, persistent CZP-ADAbs were significantly associated with reduction in plasma drug concentrations; transient expression of CZP-ADAbs were not associated with reduced plasma drug concentration. These data are consistent with studies of infliximab in patients with inflammatory bowel disease that showed transient ADAb was associated with a higher rate of clinical response compared with persistent antibodies. [16] [17] [18] The presence of transient ADAbs was associated with a continuous clinical response in most patients, whereas persistent ADAbs were associated with loss of response in all patients, suggesting that patients who are responding to treatment and who test positive for ADAbs may need longer additional evaluation before adjustments are made to treatment. 16, 18 Recent data have shown that CZP-ADAbs may develop early in treatment, 25 but it is not known if the timing of ADAb appearance influences the transient or persistent expression.
CRP and FCP are demonstrated markers of inflammation in Crohn's disease and predictors of sustained response or remission during maintenance therapy 1,4,5 and may be useful as surrogate markers for endoscopic outcomes. 4, 8, 26, 27 FCP, in particular, has shown good correlation with endoscopic findings, 28 and seems to be a sensitive indicator of endoscopic remission. 29 The data herein suggest that transient CZP-ADAb has little or no effect on these biomarkers, whereas persistent expression has detrimental effects. However, because the PRECiSE 3 study did not include endoscopic observations, additional prospective studies would be needed to determine the association between ADAbs and mucosal healing. The sharp decline in CRP concentrations toward the end of the study was likely due to discontinuations.
Patients with persistent CZP-ADAbs discontinued the study more quickly and at a higher rate than those with transient or negative ADAbs. These data are consistent with another study that showed persistent infliximab-ADAbs were associated with a significantly higher risk of treatment discontinuation versus transient ADAbs (relative risk, 5.1; 95% confidence interval, 1.4-19; P ¼ 0.0005). 18 The application of these findings to clinical practice requires some thought. For the patients who develop CZPADAbs during treatment, continued observation with serial measurements may be required to characterize transient or persistent expression. During extended observation, those with persistent CZP-ADAb positivity are at risk of being undertreated.
Concomitant use of anti-TNFs with immunomodulators which may diminish immunogenicity and clearance of anti-TNF biologics have been associated with reduction in ADAb appearance in patients with Crohn's disease. 30, 31 In this study, treatment with immunomodulators at baseline resulted in a lower percentage of patients who developed persistent CZP-ADAb-positive results (19%) compared with transient (33%) negative for CZP-ADAbs (40%). Long-term ($90 d) immunomodulator treatment concomitant with CZP may have contributed to lower rates of persistent ADAb positivity. Other studies and analyses have shown that concomitant methotrexate or immunomodulators reduce the likelihood of developing ADAb (4% with immunomodulators versus 20% without), 32 or can reduce the rate of ADAb by up to 47% relative to treatment without concomitant immunomodulators or methotrexate. 33 Treatment decisions will require clinical judgment and an account of the patient's clinical condition.
Study Limitations
One limitation of this analysis is that the study was not prospectively designed for the outcome of transient or persistent CZP-ADAb expression. This analysis also looked at inflammatory biomarkers which have been correlated with mucosal healing, 7, 8 but endoscopic observations were not part of the study design so conclusions regarding effect on mucosal healing are limited. In addition, the assay for measuring CZP-ADAb may have been compromised by drug-ADAb complexes. Therefore, the definition of ADAb positivity included a simultaneous reduction in plasma concentrations of CZP, which is measured in a separate assay. It is worth noting that the definition of transient CZP-ADAbs included temporary reductions in plasma CZP levels and the observed results fit the definition. Caution is warranted when interpreting the results because of the relatively small population of transient CZP-ADAb-positive patients.
CONCLUSIONS
These 7.5-year PRECiSE studies provided the opportunity to assess longitudinal patterns of CZP-ADAb expression and their effects on drug concentrations and markers of inflammation. Persistent, but not transient CZP-ADAbs, were associated with reduced CZP plasma concentrations during long-term therapy. Differences in CZP plasma concentrations can affect inflammatory biomarkers CRP and FCP during long-term therapy. These data provide important information for the assessment of disease activity and treatment progress.
